ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery

April 14, 2021

SINGAPORE and SAN DIEGO – April 14, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a $14 million fundraising round led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC) and new investor EDBI, an […]

T cells recognize recent SARS-CoV-2 variants (NIAID, Johns Hopkins University, & ImmunoScape Collaboration)

March 30, 2021

ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University to better understand if the CD8+ T-cell responses from COVID-19 recovered individuals still recognize the major SARS-CoV-2 variants. Out of 45 mutations assessed from the SA, UK and Brazil variants, only one mutation within the SA variant, B.1.351 Spike protein overlapped with […]

Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus vaccine

March 9, 2021

Valo Therapeutics Limited (Valo Tx), the developer of novel and adaptable immunotherapy platforms for cancer and infectious diseases, today announced the completion of a successful collaboration with the biotechnology company ImmunoScape (Singapore and San Diego) to identify immunogenic peptides for the development of a pan Coronavirus vaccine.

Geoff Nosrati

ImmunoScape Announces Chief Business Officer to Lead U.S. Expansion

February 22, 2021

Biotech executive Geoff Nosrati, Ph.D. has been named Chief Business Officer as the company expands to San Diego to accommodate growing list of U.S. partnerships

ImmunoScape Establishes Scientific Advisory Board of Distinguished Immunology Experts

January 28, 2021

World-class scientists and physicians from Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital, Massachusetts General Hospital and Harvard Medical School, will provide unique research perspectives and strategic direction 

Johns Hopkins University/NIAID Collaboration

January 26, 2021

ImmunoScape is thrilled to announce its collaboration with Johns Hopkins University/NIAID to deeply profile the SARS-CoV-2-specific CD8 T cell response in COVID-19 recovered donors. Gaining insights into T cells that interact with specific regions of the SARS-CoV-2 virus, and  provide long-lasting immunity against COVID-19, may help spur development of the next generation of vaccines. Press […]

ImmunoScape wins Emerging Enterprise Award 2020

December 11, 2020

ImmunoScape won Singapore’s most prestigious Emerging Enterprise Award organized by Business Times and OCBC Bank. Emerging Enterprise Award honors the bold ambition of Singapore’s young businesses. It is a celebration of business innovation, resilience and excellence in SMEs. The award is for “demonstrating an enterprising mindset and displaying potential for significant and sustainable growth”. Click here […]

Massachusetts General Hospital Collaboration

October 20, 2020

In the fight against COVID-19, ImmunoScape is joining forces with Dr. Patrick Reeves, Team Leader at the Massachusetts General Hospital Vaccine & Immunotherapy Center, using its signature assay, TargetScape, to perform high-dimensional immune profiling of COVID-19 induced changes across immune populations and phenotypes with a focus on antigen-specific T cells. The study will investigate the […]

Arcturus Collaboration

August 20, 2020

As part of a collective effort in fighting COVID-19, ImmunoScape is collaborating with Arcturus Therapeutics, a developer of RNA therapeutics for treatment and prevention of diseases with high unmet medical needs, and Duke-NUS, who will be running the clinical trial in healthy subjects in Singapore. The Arcturus LUNAR-COV19 vaccine, which uses Arcturus proprietary STARR™ and LUNAR® technologies is […]

ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology with $11M in Global Financing Led by Anzu Partners and UTEC

August 11, 2020

The funds enable ImmunoScape to bring its unique immune-profiling capability to major biopharma companies globally, accelerating development of vital immunotherapies and other medicines